Eaton Bruce
Known title: EVP, Chief Business OfficerCIK: 0001874831
Associated companies
Transaction History
| EDIT | ▼ Sell | Open Market | 103 | $1K | 12/5/2023 | View on chart |
| EDIT | ▼ Sell | Open Market | 695 | $6K | 11/14/2023 | View on chart |
| EDIT | ▼ Sell | Open Market | 139 | $1K | 11/7/2023 | View on chart |
| EDIT | ▼ Sell | Open Market | 103 | $908 | 9/6/2023 | View on chart |
| EDIT | ▼ Sell | Open Market | 702 | $6K | 8/11/2023 | View on chart |
| EDIT | ▼ Sell | Open Market | 141 | $1K | 8/8/2023 | View on chart |
| EDIT | ▼ Sell | Open Market | 105 | $998 | 6/5/2023 | View on chart |
| EDIT | ▼ Sell | Open Market | 668 | $7K | 5/11/2023 | View on chart |
| EDIT | ▼ Sell | Open Market | 135 | $1K | 5/9/2023 | View on chart |
| EDIT | ▼ Sell | Open Market | 101 | $898 | 3/3/2023 | View on chart |
| EDIT | ▲ Buy | Grant | 16,700 | $0 | 3/2/2023 | View on chart |
| EDIT | ▼ Sell | Open Market | 3,307 | $32K | 2/13/2023 | View on chart |
| EDIT | ▼ Sell | Open Market | 346 | $4K | 2/7/2023 | View on chart |
| EDIT | ▼ Sell | Open Market | 102 | $1K | 12/5/2022 | View on chart |
| EDIT | ▼ Sell | Open Market | 289 | $3K | 11/8/2022 | View on chart |
| EDIT | ▼ Sell | Open Market | 101 | $2K | 9/6/2022 | View on chart |
| EDIT | ▼ Sell | Open Market | 293 | $5K | 8/9/2022 | View on chart |
| EDIT | ▼ Sell | Open Market | 1,123 | $13K | 6/3/2022 | View on chart |
| EDIT | ▼ Sell | Open Market | 297 | $4K | 5/9/2022 | View on chart |
| EDIT | ▼ Sell | Open Market | 1,258 | $25K | 4/1/2022 | View on chart |
| EDIT | ▼ Sell | Open Market | 403 | $7K | 3/3/2022 | View on chart |
| EDIT | ▲ Buy | Grant | 37,593 | $0 | 2/10/2022 | View on chart |
| EDIT | ▼ Sell | Open Market | 302 | $5K | 2/8/2022 | View on chart |
| EDIT | ▲ Buy | Grant | 3,472 | $0 | 12/22/2021 | View on chart |
| EDIT | ▼ Sell | Open Market | 287 | $12K | 11/9/2021 | View on chart |
| EDIT | ▼ Sell | Open Market | 287 | $16K | 8/9/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Editas Medicine upgraded to Buy with $5 price target
Guggenheim upgraded Editas Medicine to Buy and set a $5 price target, citing a planned BLA filing in 2027 and progress with PM647. This move came as gene-editing stocks faced broader pressure from recent AI-related news. The upgrade aligns with the current average analyst target of $5.90, providing a positive fundamental signal for the stock.
Editas Medicine upgraded to Buy with $5 price target. Guggenheim upgraded Editas Medicine to Buy and set a $5 price target, citing a planned BLA filing in 2027 and progress with PM647. This move came as gene-editing stocks faced broader pressure from recent AI-related news. The upgrade aligns with the current average analyst target of $5.90, providing a positive fundamental signal for the stock.